Key facts
- Apreo Health’s last known valuation is $183.0M (Aug 2025).
- It has raised $153.6M across 1 recorded rounds; the latest was Later Stage VC ($81.8M) in Aug 2025.
- Notable investors include F-Prime Capital, Norwest, Lightstone Ventures, Bain Capital Life Sciences, Intuitive Ventures — 8 tracked in total.
- Apreo Health has filed 1 Form D with the SEC, most recently Aug 2025 ($81.8M sold to 7 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Apreo Health
Funding rounds
1 roundsAbout Apreo Health
Developer of investigational medical devices designed to treat severe emphysema by reducing lung hyperinflation. The company offers a bronchoscopically delivered implant featuring a proprietary scaffold engineered to release trapped air from the lungs, resist foreign body reactions and promote durability of effect, enabling healthcare providers to manage chronic obstructive pulmonary disease in patients with emphysema by improving lung function and quality of life through a minimally invasive approach.
- Sector
- Healthcare
- HQ
- Menlo Park, CA, United States
- Founded
- 2021
- Employees
- 20
- Website
- apreohealth.com/
- Ownership
- Privately Held (backing)
Apreo Health doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Apreo Health shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Apreo Health in its N-PORT filings yet. We sweep new filings monthly.